Tag Archives: direct oral anticoagulants (DOACs)

Background Atrial fibrillation (AF) occurs at an increased frequency in patients with cancer, however, the link between cancer and AF is not fully understood.1,2 Stroke prophylaxis with anticoagulation is important; however, this can prove challenging in the setting of active malignancy, which predisposes to an increased risk of haemorrhage, as well as thrombosis.3 Traditionally, low molecular weight heparin (LMWH) and warfarin have been used in this setting. There remains limited evidence for direct oral anticoagulants (DOACs) in cancer patients for stroke prophylaxis in AF (SPAF). However, small observational studies have demonstrated compa